HDAC1 and neoplasm: Chidamide, a novel histone deacetylase (HDAC) inhibitor that targets HDAC1, 2, 3, and 10, demonstrated robust antitumor activity by inducing tumor cell apoptosis and differentiation, inhibiting tumor angiogenesis and metastasis, and enhancing the immune system’s cytotoxic effect on tumors (15).